Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply

JAMA Oncol. 2021 Jan 1;7(1):137. doi: 10.1001/jamaoncol.2020.5591.

Authors

Caroline Caramella¹, Roberto Ferrara², Benjamin Besse³

Affiliations

¹ Radiology Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
² Department of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
³ Cancer Medicine Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

PMID: 33211070
DOI: 10.1001/jamaoncol.2020.5591

No abstract available

Publication types

Letter
Comment

MeSH terms

Disease Progression
Humans
Immunologic Factors*
Immunotherapy* / adverse effects

Substances

Immunologic Factors